SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/NeurotrophicResearch peptide

Cerebrolysin

aka FPF-1070

Porcine brain-derived peptide mixture studied in stroke, TBI, and neurodegeneration.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Cerebrolysin is a standardized mixture of low-molecular-weight neuropeptides and amino acids derived from purified porcine brain protein.

Source
  • Manufactured pharmaceutical preparation
Forms
  • Intramuscular and intravenous injection

Mechanism of action

Mimics endogenous neurotrophic factor activity, supporting neuronal survival, synaptic plasticity, and recovery after injury.

Pathways
  • · BDNF-like activity
  • · NGF-like activity
  • · PI3K-Akt survival signaling
  • · Reduced excitotoxicity

How it acts on the body

Cerebrolysin behaves like an exogenous neurotrophic factor cocktail. In ischemic stroke trials it has shown modest improvement in early neurologic recovery when started within 72 hours, and in TBI and vascular dementia trials it has shown cognitive and functional benefits, though heterogeneity across studies is high.

Mechanistically, it reduces calcium-mediated excitotoxicity, supports mitochondrial function in stressed neurons, and shifts the balance toward synaptic plasticity over apoptosis in the penumbra of injured tissue.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

BDNF signalingIncreases
Mimics BDNF-mediated survival cues.
Glutamate excitotoxicityDecreases
Calcium-mediated neuronal injury attenuated.
Cortisol stress responseStabilizes
Indirect via reduced injury severity.

Effects on the body

Supports
Post-stroke functional recovery
Supports
Cognitive function in vascular dementia
Decreases
Excitotoxic neuronal injury

Organ system effects

Brain & CNS

Primary site — neurotrophic and neuroprotective signaling.

Endocrine

Limited systemic endocrine effects.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Decades of clinical use in Europe and Asia
  • Multimodal neurotrophic action

Potential side effects

Common
  • · Injection-site reaction
  • · Sweating
  • · Vertigo
Rare
  • · Tachycardia
  • · Insomnia
Serious
  • · Rare hypersensitivity reactions

Drug interactions

MAO inhibitors
Theoretical interaction; concomitant use generally avoided.
moderate

Pairing context

Often combined with
  • Structured rehabilitation post-stroke
    Neurotrophic support amplifies activity-driven plasticity.
Avoid combining with
  • Status epilepticus or severe renal impairment
    Listed contraindications in product labeling.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.